Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
August 12, 2013 – Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists
PHILADELPHIA — GenoSpace, PathGroup and the IP & Science businessof Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.
This partnership combines resources, technology and expertise across the three organizations to integrate PathGroup’s SmartGenomics™ Next Generation DNA Sequencing and Cytogenomic Array with traditional pathology assays, providing a unique window into disease and patient treatment options through genetic profiling.
“Collaboration is essential to deliver more precise medical solutions in today’s Big Data environment,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. “Our coalition with GenoSpace and PathGroup leverages each organization’s unique assets, making significant improvements in treatment options for cancer patients.”
PathGroup’s industry-leading anatomic, clinical and molecular pathology services are integrated with the unparalleled information on genes, variants and therapeutic implications from Thomson Reuters. These are then overlaid with GenoSpace’s advanced analytical and information integration capabilities to place this diverse data into context. Oncologists will soon start receiving individualized reports that provide targeted information to help identify the best possible therapy for their patients. Rest